Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study

Hannah C. Slater PhD (1)*, Prof Brian D. Foy PhD (2), Kevin Kobylinski PhD (3), Carlos Chaccour MD (4,5,6), Oliver J. Watson MRes (1), Joel Hellowell PhD (1), Ghaith Aljayyoussi PhD (7), Teun Bousema PhD (8,9), Jeremy Burrows PhD (10), Prof Umberto D’Alessandro PhD (11), Haoues Alout PhD (12), Prof Feiko Ter Kuile PhD (7), Patrick G.T. Walker PhD (1), Prof Azra C. Ghani PhD (1), Menno R. Smit MD (7)

1) MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK
2) Arthropod-borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA
3) Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand
4) ISGlobal, Hospital Clinic - Universitat de Barcelona, Barcelona, Spain
5) Instituto de Salud Tropical - Universidad de Navarra, Pamplona, Spain
6) Ifakara Health Institute, Ifakara, Tanzania
7) Liverpool School of Tropical Medicine (LSTM), Liverpool, UK
8) Department of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, UK
9) Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands
10) Medicines for Malaria Venture, Route de Pré Bois 20, 1215 Geneva 15, Switzerland
11) MRC Unit The Gambia at LSHTM, Fajara, Banjul, The Gambia
12) ASTRE unit (UMR117), INRA-CIRAD, Montpellier, France

*Corresponding author (hslater@path.org, PATH, 2201 Westlake Avenue, Seattle, WA, USA)

Summary

Background: Ivermectin has been identified as a potential new vector control tool to reduce malaria transmission. Mosquitoes feeding on a bloodmeal containing ivermectin have been shown to have a reduced lifespan, meaning they are less likely to live long enough to complete sporogony and become infectious.

Methods: In this study, we validate an existing population-level mathematical model of the impact of ivermectin on the mosquito population and malaria transmission to entomological and clinical data. The model is extended to include a range of complementary malaria interventions and to incorporate new data on higher doses with a longer mosquitocidal effect. We then simulate the impact of these doses in a range of usage scenarios in different transmission settings.

Findings: Mass drug administration (MDA) with ivermectin is predicted to reduce prevalence and incidence and is most effective in areas with a relatively short transmission season. In a highly seasonal moderate transmission setting, three rounds of ivermectin-only MDA spaced one month apart with a dose of 3x300µg/kg and 70% coverage is predicted to reduce clinical incidence by 71% and prevalence by 34% We predict that adding ivermectin MDA to seasonal malaria chemoprevention in this setting will reduce clinical incidence by an additional 77% in under 5-year olds. Adding ivermectin MDA to MDA with antimalarials in this setting is predicted to reduce incidence by an additional 75%.
**Interpretation:** Ivermectin is a novel vector control tool that targets residual transmission, it has an excellent safety profile and has operationally synergistic distribution schedules with existing malaria interventions. Based on modelling predictions in this study, we propose that this drug could be a valuable addition to the malaria control toolbox, both in areas with persistently high transmission where existing vector control is insufficient and in areas approaching elimination to prevent resurgence.

**Funding:** Imperial College Junior Research Fellowship

**Research in context**

Evidence before this study

We searched PubMed and ScienceDirect on August 17th, 2019, for studies using mathematical models to assess the impact of ivermectin (to humans) on malaria prevalence and incidence, using the search terms “ivermectin” AND “malaria” AND (“modelling” OR “modeling”). The search was unrestricted by language or publication date. Using this search and by scanning reference lists of articles, we identified three publications in peer-reviewed journals. Slater et al. found that adding a single dose of ivermectin 200 μg/kg would only have a modest effect on reduction of malaria prevalence if distributed in mass drug administration (MDA) with dihydroartemisinin-piperaquine (DHA-P), although higher doses of ivermectin were predicted to have a greater and longer-lasting effect. However, a model developed by Stuckey and colleagues predicted that adding ivermectin to MDA with DHA-P in Zambia would have a negligible additional effect. Finally a theoretical mathematical model by Ngwa et al. predicts that treating symptomatic individuals with ivermectin would reduce the reproduction number of malaria.

Added value of this study

We present the first population-level mathematical model of the impact of ivermectin on the mosquito population and malaria transmission that has been validated to clinical and entomological field data. Furthermore, the model incorporates new empirical data on higher doses with a longer mosquitocidal effect and has been extended to assess ivermectin alone and in combination with a range of complementary malaria interventions, including mass drug administration and seasonal malaria chemoprevention. By simulating impact in a range of usage scenarios in different transmission settings, our study shows that mass drug administration with ivermectin is predicted to reduce prevalence and incidence and is most effective in areas with a relatively short transmission season. When used in combination with seasonal malaria chemoprevention or mass drug administration with antimalarials, we predict that ivermectin will increase and prolong the impact of these interventions.

Implications of all the available evidence

Our modelling results indicate that ivermectin alone, and to a greater extent when combined with antimalarial drugs, is predicted to have a major and prolonged effect on malaria prevalence and incidence in a range of transmission settings. We predict that adding ivermectin mass drug administration to current interventions can increase impact and help sustain reductions in transmission. Due to the operationally synergistic opportunities of co-administering ivermectin with other interventions that have the same distribution schedule (mass drug administration with antimalarials, and seasonal malaria chemoprevention), and the fact that ivermectin can directly target residual transmission that remains even with high coverage of long lasting insecticidal nets and indoor residual spraying with insecticides, we believe ivermectin is a powerful new tool which can complement existing malaria control efforts.
Introduction

Despite increasing coverage of vector control (long lasting insecticidal nets (LLINs) and indoor residual spraying (IRS) with insecticides) and improved access to diagnosis and treatment, there were still an estimated 435,000 deaths from malaria in 2017. Novel control methods targeting aspects of the transmission cycle currently missed by existing interventions may be needed to further reduce malaria burden. LLINs have contributed most to reductions in transmission but provide imperfect protection against human-vector contact, missing outdoor and early-biting mosquitoes. IRS targets only indoor-feeding and indoor-resting mosquitoes. Furthermore, there is evidence that mosquitoes are changing their behaviour to feed at times when people are not protected by these interventions. Worryingly, insecticide resistance to the main chemicals has been reported worldwide, resulting in reduced efficacy in killing mosquitoes.

IRS and LLINs will likely remain the cornerstones of malaria control but there is an urgent need for additional tools to supplement them. Several novel vector control approaches are being trialled, including attractive targeted sugar baits and eave tubes. Mosquitocidal drugs, such as the avermectin class of endectocides, are a potentially impactful novel approach to vector control. Endectocides work by killing mosquitoes that feed on humans or animals that have recently taken them. Ivermectin is the only drug in the class that is available for human use, and studies have shown that it is toxic to mosquitoes, delays refeeding, reduces fecundity and locomotor activity, and may inhibit sporozoite development. Ivermectin has many attractive qualities as a novel malaria control tool. Unlike IRS and LLINs, it targets mosquitoes regardless of feeding location or time. It can be given to cattle, so could be dual-administered to both humans and cattle in areas with zoophilic malaria-transmitting mosquitoes. Furthermore, it has a novel model of action, reducing the likelihood of cross-resistance with existing insecticides.

Mass ivermectin administration could be combined in an operationally opportunistic manner with current interventions already being carried out on a large scale across malaria endemic regions. Single dose mass drug administration (MDA) with ivermectin (and other anti-helminthic drugs) is carried out to control neglected tropical diseases (NTDs) across Africa - extending the dosing schedule and frequency of administration in line with the malaria transmission season could have an impact on malaria transmission. Seasonal malaria chemoprevention (SMC), the monthly distribution of antimalarial drugs to children 3-59 months old during the peak months of transmission is being implemented in 12 countries in the Sahel region of Africa. Combining SMC with population-wide ivermectin distribution could further protect children from being re-infected and reduce malaria transmission. Finally, MDA with antimalarials has been trialled in several malaria endemic countries to either accelerate toward elimination, reduce malaria burden or contain the spread of artemisinin resistant parasites through local elimination; ivermectin could be combined with this intervention to increase and prolong impact.

The doses of ivermectin typically used for onchocerciasis and lymphatic filariasis control (single doses of 150-200µg/kg) have a short mosquitocidal effect of around 5-6 days and limited impact on mosquito populations and transmission unless distributed frequently. Recent clinical trials investigating the impact of higher doses have produced promising results. Three doses of 300µg/kg given over three days has a mosquitocidal effect in humans for 28 days against Anopheles gambiae s.s. and a single dose of 400µg/kg was effective for at least ten days against Anopheles minimus and 6-10 days against Anopheles dirus, two of the most important malaria vectors in Southeast Asia. A slow-release ivermectin implant has achieved mosquitocidal concentrations for 40 weeks in cattle, and a novel slow-release, gastric-resident, drug delivery technology in development has achieved
mosquitocidal concentrations of ivermectin for around 14 days in pigs\textsuperscript{23}. Fluralaner and afoxolaner, two drugs from the isoxazolines class of endectocides used in veterinary medicine, have also been shown to be toxic to mosquitoes. Preliminary estimates indicate that they could remain at effective mosquitocidal concentrations for 50-90 days, but have not yet been tested for safety in humans\textsuperscript{24} and regulatory approval for human use may take up to a decade\textsuperscript{25}. The combination of non-ivermectin mosquitocidal drugs administered to cattle alongside ivermectin administered to humans has been suggested as an approach to simultaneously target anthropophilic and zoophilic mosquitoes whilst preventing the development of resistance to ivermectin via a dual-chemistry approach which is recommended in other forms of vector control\textsuperscript{26}.

The growing body of evidence that higher doses of ivermectin have a prolonged efficacious duration, as well as the development of other slow release or long lasting endectocides has led to calls to better understand the potential impact of these drugs on malaria transmission\textsuperscript{17}. In this study, we use a mathematical model to estimate the impact of ivermectin MDA and to provide guidance on the potential scenarios in which they could complement existing malaria interventions to further reduce malaria transmission and burden.

**Methods**

We previously developed a malaria transmission model\textsuperscript{27} to capture the impact of ivermectin\textsuperscript{28} on vector survival. Here we extend the model to: i) incorporate a range of complementary malaria interventions, ii) allow a wider range of mosquitocidal drug profiles, iii) track the parity rate of vector populations, and iv) allow for correlation between who receives drugs each round in mass administration interventions.

**Malaria transmission model**

The deterministic compartmental model incorporates transmission between mosquito and human hosts\textsuperscript{27,29}. Individuals begin life susceptible with a level of maternally-acquired immunity which quickly wanes. Upon inoculation with an infectious bite they either become infected (with probability determined by their level of pre-erythrocytic immunity), whereupon they either develop clinical disease or asymptomatic infection (determined by their levels of blood-stage immunity). Individuals with clinical disease have a probability of being successfully diagnosed and treated. Treated individuals are prophylactically protected for a duration based on the properties of the antimalarial taken. Untreated individuals with clinical disease are assumed to have symptomatic infection for an average 5 days before transitioning to becoming asymptotically infected. Asymptomatically infected individuals remain infected for an average 310 days\textsuperscript{27}, but their probability of being detectable by microscopy decreases over the course of the infection to capture the effect of decreasing parasite densities. Individuals that are susceptible or have asymptomatic infection can be superinfected which follows the same infection process. The acquisition and loss of immunity is dynamically modelled and determines the probability of infection, the probability of developing symptoms and the detectability and transmissibility of infection. Transmission from mosquitoes to humans is determined by the entomological inoculation rate, which is a product of the mosquito biting rate, sporozoite rate, functions determining the relative biting rate on different subgroups (capturing heterogeneity in exposure) and age and the probability of successful inoculation. Similarly, transmission from humans to mosquitoes is determined by the infectivity of the human, which is based on their infection state, the mosquito biting rate, the age- and heterogeneity-biting rates and the probability of successful infection. We assume a constant and isolated population, with no movement of infected humans or mosquitoes in or out of the intervention area. Details of the model are provided in the Appendix, page 1-11.
**Intervention models**

We assess the impact of ivermectin MDA by assuming that a proportion of bloodmeals taken by mosquitoes contain ivermectin (determined by the coverage of ivermectin in the human population). Mosquitoes ingesting ivermectin transition to a new compartment where they experience an elevated mortality rate for the rest of their life. The ‘ivermectin-fed’ compartments are tracked for each day post ivermectin-administration, each with a unique mortality rate to capture the elevated but waning mosquitocidal effect of ivermectin over time as the concentration in human blood decreases. The elevated mortality rates are estimated using a pharmacokinetic (PK)-pharmacodynamic (PD) model which has been fitted to human ivermectin plasma concentrations and corresponding mosquito mortality data from feeding experiments conducted using *Anopheles gambiae sensu stricto* Delayed refeeding, reduced egg laying and reduced sporogonic development are not explicitly modelled as these effects are minimal compared to the mosquitocidal effects. We also incorporate the impact of existing malaria interventions – including LLINs, SMC and MDA – using existing intervention models.

**Model validation**

The model is validated against data from two ivermectin trials: a study across three countries consisting of a single round of ivermectin MDA and focusing on entomological data, and a cluster randomised trial (CRT) conducted in Burkina Faso consisting of a single round of ivermectin MDA in the control arm and six rounds of ivermectin MDA in the intervention arm and focusing on clinical incidence in a cohort of children ≤5 years old. This model validation is presented in the Appendix, pages 12-17.

**Intervention Scenarios**

We explore the potential impact of ivermectin on malaria prevalence and clinical incidence for the scenarios shown in Box 1. The scenarios are simulated in three seasonality ‘archetypes’ that encapsulate the range of transmission in sub-Saharan Africa: i) highly seasonal, based on Fatick in Senegal, with a transmission season of approximately 4 months, ii) seasonal, based on Bougouriba in Burkina Faso, with a season of 7-8 months, and iii) perennial, based on Equateur in Democratic Republic of Congo (DRC), with year-round transmission. Unless stated otherwise, all simulations have a mean annual all-age slide prevalence of 30%.

Ivermectin is recommended for all individuals >15kg / ≥90cm, however, for simplicity we assume all children <59 months are below this threshold, and all children ≥59 months are above this threshold. Coverage of ivermectin is defined using the number of all individuals ≥5 years old as the denominator. Ivermectin is also not recommended for pregnant women, which is why we only consider modest coverage estimates (maximum of 70%).

We consider two ivermectin regimens: a single dose of 400µg/kg (1x400) and three consecutive daily doses of 300µg/kg per day (3x300). The former is the highest dose currently recommended for lymphatic filariasis MDAs, and the latter is the dose that was viewed as most promising in a recent clinical trial.

For all scenarios the intervention is introduced optimally in relation to the location-specific seasonality profile of each simulation, obtained by simulating the model at different start times and selecting the time that results in the greatest reduction in cumulative incidence.
Role of Funding Source

The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

The estimated pharmacokinetic profiles of the two dosing regimens are shown in Figure 1a. These were combined with the mosquito hazard ratios estimated in Smit et al.\textsuperscript{20} for each time after ivermectin administration that mosquitoes were fed on the treated individuals’ blood (day 2+4 hours, d7, d10, d14, d21, d28) to estimate the relationship between drug concentration and the mosquito hazard ratio (Figure 1b). Figures 1a-b were then combined to estimate the daily hazard of mortality of mosquitoes biting each day (Figure 1c).

Ivermectin only MDA

We first simulated the impact of ivermectin only, assuming all other interventions continued at their current coverage levels (Figure 2, Table 1). The impact of ivermectin is predicted to be greatest in the setting with the shortest transmission season, with a predicted reduction in clinical incidence of 62% and 71% for the 1x400µg/kg and 3x300µg/kg doses respectively. The intervention is predicted to be less effective in areas with perennial transmission, where the equivalent reductions are 28% and 31% respectively. We predict that ivermectin has a greater impact on incidence than on prevalence. This is because the intervention prevents new infections by killing infected and infectious mosquitoes rather than clearing older asymptomatic infections. The sensitivity of these results to the impact of repeat ivermectin distribution assuming different durations and magnitudes of mosquitocidal effect (including a hypothetical mosquitocidal drug with a 90-day efficacious period), population coverage levels, number of rounds and timing between rounds and transmission intensities, and exploring the impact of importation of infected individuals into the intervention area, as well as synergies between interventions is shown in the Appendix, pages 18-28.

Ivermectin MDA with SMC

Figure 3 and Table 1 show the estimated impact of population-wide ivermectin MDA in combination with SMC. Adding ivermectin MDA is predicted to increase the reduction in clinical cases in children <5 years old compared to SMC alongside existing core interventions. In a highly seasonal setting, we predict that SMC alone reduces clinical cases by 58% but adding population-wide ivermectin MDA increases this figure to 87% (1x400µg/kg) or 90% (3x300µg/kg) in the year after the start of the intervention. This corresponds to an incremental impact on top of SMC alone of 69% and 77%, respectively. The reduction in clinical incidence is predicted to be lower in a setting with a longer transmission season. Here, the incremental impact of ivermectin is 51% (1x400µg/kg) and 58% (3x300µg/kg). The impact of expanding SMC distribution to all individuals under the age of 10 (alongside ivermectin to individuals over the age of 10) is shown in the Appendix, pages 25-26.

Delivering SMC to children <5 years old and ivermectin MDA population-wide (≥5 years old) is also predicted to have a dramatic impact on population level prevalence – whereas SMC alone is predicted
to reduce all-age prevalence by only 19-21%, adding ivermectin (1x400 µg/kg dose) is predicted to reduce all-age prevalence by 52% (highly seasonal setting) or 45% (seasonal setting).

**Ivermectin and DHA-P MDA for burden reduction**

The impact of MDA with DHA-P and ivermectin for burden reduction in a highly seasonal moderate transmission setting with three rounds spaced one month apart is shown in Fig. 4a,d, and in a perennial moderate transmission setting with three rounds spaced one month apart in Fig. 4b,e or three rounds spaced four months apart in Fig. 4c,f. MDA with DHA-P and ivermectin is predicted to be most effective in a seasonal transmission setting; predicted reduction in clinical incidence is 91% (DHA-P + 1x400µg/kg ivermectin) and 94% (DHA-P + 3x300µg/kg ivermectin) compared to 74% with DHA-P alone (Table 1). In a perennial setting, a greater reduction in burden is achieved by spacing the rounds evenly throughout the year – in this scenario, the incremental impact of ivermectin in addition to DHA-P is also greater (Table 1).

**Ivermectin and DHA-P MDA for elimination**

Figure 5 shows the impact of MDA with DHA-P and ivermectin in a seasonal low transmission setting. Here adding ivermectin to DHA-P prevents the rebounds in transmission between rounds and is predicted to prolong the overall impact of the MDA intervention.

**Discussion**

Our modelling results predict that ivermectin alone, and to greater extent when combined with antimalarial drugs, could have a major and prolonged effect on malaria prevalence and incidence across a range of transmission settings. We predict that adding ivermectin MDA to current interventions can increase impact and sustain reductions in transmission. Due to the operationally synergistic opportunities of co-administering ivermectin with other interventions that have the same distribution schedule (MDA with antimalarials, SMC), and the fact that ivermectin can directly target residual transmission that remains even with high coverage of vector control, ivermectin may be a promising new complementary malaria tool.

In a seasonal setting, adding ivermectin MDA to SMC has a greater incremental impact on reducing prevalence and incidence compared to adding ivermectin MDA to DHA-P MDA, however the total impact of the latter intervention is greater. During SMC, a large proportion of the population remain untreated and unprotected, therefore adding an intervention that reduces the infectious vector population means that these individuals will also receive a benefit. However, MDA with DHA-P provides prophylaxis to a larger proportion of the population, so reducing the infectious vector population with ivermectin has a lower additional impact as a large proportion cannot be re-infected anyway.

SMC is widely conducted, extremely effective, and a key intervention in in the Sahel region which experiences some of the highest rates of malaria worldwide. We predict that administering ivermectin to the population ≥5 years old could not only increase the impact of SMC in children under 5, but could also increase the population-level benefit, reducing clinical incidence across the whole population.

Our results suggest that the 3x300µg/kg dose is only marginally more impactful than the 1x400µg/kg dose. Although the hazard-ratio area under the curve (and above 1) is 78% greater for 3x300 µg/kg compared to 1x400µg/kg (Figure 1c), the highly non-linear effect of increased mortality on the proportion of mosquitoes completing sporogony and becoming infectious means that the duration the hazard ratio is above some threshold is more important that the magnitude of the hazard ratio. Even for a hazard ratio of 2, the proportion of mosquitoes surviving long enough to complete
sporogony is 63% lower than in the absence of ivermectin. The hazard ratio is >2 for 14 days with 3x300 μg/kg and for 10 days with 1x400 μg/kg. The difference between the two regimens is greater in a highly-seasonal compared to a perennial setting (Figure 2) because, with the former, ivermectin’s effective window covering a greater proportion of annual transmission.

A key assumption in the ivermectin component of the model is that the hazard ratios observed in a clinical laboratory setting can be applied to the known mortality rates of wild mosquitoes. For example, we assume that a mosquito dying twice as quickly in the laboratory after a certain dose of ivermectin would also die twice as quickly in the wild, albeit with a considerably higher baseline mortality rate. In the model, we assume that the mean baseline lifespan of an Anopheles gambiae mosquito is 10 days in the wild whereas the lifespan of mosquitoes in laboratory experiments is around 14-30 days\textsuperscript{20,32}.

The model accurately captures changes in entomological outcomes observed in the field; however, these field data are limited (Appendix, page 14). Future entomology data collected in CRTs is therefore needed to validate or refine this assumption. The results presented here assume all mosquitoes are Anopheles gambiae s.s., however, there is no evidence that other African vectors would be less sensitive\textsuperscript{12,32,33}.

Further limitations include that the 3x300µg/kg hazard estimates were derived directly from data\textsuperscript{13} whereas the 1x400µg/kg hazard ratios were estimated using a PK-PD model. The data used to derive both sets of hazard ratios were from a trial where ivermectin was co-administered with DHA-P. Preliminary data suggest an interaction between these drugs that increases ivermectin bioavailability, peak concentration, and mosquito killing effect compared to that of ivermectin alone\textsuperscript{21}. Additionally, it remains to be determined whether the observed effect of ivermectin solely reflects that of the parent compound, or whether there is also an active ivermectin metabolite with mosquitocidal properties\textsuperscript{21}.

The results presented here assume a constant and isolated population, with no movement of infected humans or vectors into or out of the intervention area. Although in a sensitivity analysis (see Appendix, pages 24-25) we did not find a major impact of this assumption, further exploration of the effect of this intervention in models that capture spatial linkage between populations is warranted.

To provide empirical evidence for the utility of ivermectin across different settings CRTs are needed. An earlier small CRT of repeated ivermectin MDA in Burkina Faso\textsuperscript{19} found a 19.6% reduction in episodes of clinical incidence in a cohort of children ≤5 years old (Appendix, pages 15-17). Whilst the 1x400μg/kg dose has been used for lymphatic filariasis control, the 3x300μg/kg dose has never been delivered at scale to whole populations. An ongoing CRT in The Gambia (NCT03576313) will provide evidence on the safety and acceptability of this higher dose (3x300 µg/kg) when given in combination with DHA-P. Questions remain surrounding the feasibility of delivering this intervention at scale and the implications and potential adherence issues of treating populations with a drug that may provide them no direct benefits (if they do not have any other infections that ivermectin treats).

The appetite from national malaria control programs and funders to implement ivermectin MDA still needs to be ascertained. These decisions will depend in part on estimates of cost-effectiveness in comparison to other malaria interventions, particularly other novel vector control tools that might be targeted in areas with high transmission and high coverage of existing vector control tools. Mass ivermectin distribution in Loaisa-endemic regions may require a test-and-not-treat strategy, as it can cause adverse events in Loa loa infected individuals\textsuperscript{34}. 

8
New longer lasting ivermectin formulations or other mosquitocidal drugs offer a promising new opportunity for malaria control, however, the benefit of current formulations of ivermectin should not be underplayed. Ivermectin is known to be safe and accepted by communities who have received MDAs for decades as part of the control of lymphatic filariasis and onchocerciasis. Ongoing CRTs using ivermectin will provide an opportunity to evaluate the impact of mosquitocidal drugs and provide evidence to guide decision making for both current and new longer lasting versions of these drugs.

As of September 2019, in addition to the ivermectin CRT underway in The Gambia, there are four more trials (that we are aware of) planned to start in 2019 or 2020. These trials are being conducted in different transmission settings with different doses and distribution schedules, different malaria vectors, and different coverages of other interventions. Models that have been validated against clinical and entomological data, such as the one presented here, will offer a useful way to compare results from these diverse trials, to synthesise evidence, and provide a robust framework to extrapolate from these trials to wider-scale predictions.
Disclaimers

Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.

ISGlobal is a member of the CERCA Programme, Generalitat de Catalunya

Funding Sources

This work was funded by an Imperial College Junior Research Fellowship to HCS with additional financial support from the Bill and Melinda Gates Foundation.

HCS and CC received additional financial support from Bill and Melinda Gates Foundation under the Ivermectin development roadmap (OPPP1177135) and from Unitaid under the Project Preparation Facility of the BOHEMIA grant (2018-30-ISG)

Contributors

HCS performed the transmission modelling analysis and processed all model outputs. HCS, BDF, KK, CC, TB, PGTW, MRS designed the analysis. GA produced the PK/PD modelling outputs. BDF, KK, HA, FTK, MRS collected data. HCS, OJW, JH developed the model code. HCS wrote the first draft of the manuscript. All authors contributed to writing and editing the manuscript. All authors approved the final manuscript.

References


19 Foy, B. *et al.* Repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomized trial to evaluate efficacy and risk of harms. *Lancet* ((in press)).


Box 1: Details of intervention scenarios

<table>
<thead>
<tr>
<th>Complementary intervention</th>
<th>Ivermectin interventions</th>
<th>Intervention Frequency</th>
<th>Example transmission setting</th>
</tr>
</thead>
</table>
| Continue standard interventions already in place (LLINs, access to diagnosis and treatment) | • None  
• Ivermectin-1x400 MDA  
• Ivermectin-3x300 MDA | 3 rounds one month apart | Highly seasonal (based on Fatick, Senegal), moderate transmission  
Seasonal (based on Bougouriba, Burkina Faso), moderate transmission  
Perennial (based on Equateur, DRC), moderate transmission |
| SMC (with sulfadoxine-pyrimethamine and amodiaquine (SP-AQ)) to children 3-59 months old and continue standard interventions | • None  
• Ivermectin-1x400 MDA  
• Ivermectin-3x300 MDA | 4 rounds one month apart | Highly seasonal (based on Fatick, Senegal), moderate transmission  
Seasonal (based on Bougouriba, Burkina Faso), moderate transmission |
| MDA (with dihydroartemisinin-piperaquine (DHA-P)) to all eligible population and continue standard interventions | • None  
• Ivermectin-1x400 MDA  
• Ivermectin-3x300 MDA | 3 rounds one month apart | Highly seasonal (based on Fatick, Senegal), moderate transmission  
Perennial (based on Equateur, DRC), moderate transmission  
Highly seasonal (based on Fatick, Senegal), low transmission |
|  |  | 3 rounds four months apart | Perennial (based on Equateur, DRC), moderate transmission |
### Ivermectin only

<table>
<thead>
<tr>
<th>Ivermectin dose</th>
<th>Percentage reduction in clinical incidence in all population over 1 year after start of intervention</th>
<th>Percentage reduction in mean slide prevalence in all population over 1 year after start of intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highly seasonal (Fatick, Senegal)</td>
<td>1x400µg/kg: 62% 3x300µg/kg: 71%</td>
<td>1x400µg/kg: 27% 3x300µg/kg: 34%</td>
</tr>
<tr>
<td>Seasonal (Bougouriba, BF)</td>
<td>1x400µg/kg: 49% 3x300µg/kg: 55%</td>
<td>1x400µg/kg: 21% 3x300µg/kg: 26%</td>
</tr>
<tr>
<td>Perennial (Equateur, DRC)</td>
<td>1x400µg/kg: 28% 3x300µg/kg: 31%</td>
<td>1x400µg/kg: 13% 3x300µg/kg: 15%</td>
</tr>
</tbody>
</table>

### SMC and ivermectin MDA

<table>
<thead>
<tr>
<th>Complementary intervention</th>
<th>Percentage reduction in clinical incidence in children &lt;5 years old over 1 year after start of intervention (compared to baseline)</th>
<th>Percentage reduction in clinical incidence in children &lt;5 years old over 1 year after start of intervention (compared to SMC only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin dose</td>
<td>SMC to children &lt;5 years old</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>1x400µg/kg: 58% 3x300µg/kg: 87% 1x400µg/kg: 69% 3x300µg/kg: 77%</td>
<td>1x400µg/kg: 48% 3x300µg/kg: 75% 1x400µg/kg: 51% 3x300µg/kg: 58%</td>
</tr>
</tbody>
</table>

### MDA with DHA-P and ivermectin

<table>
<thead>
<tr>
<th>Complementary intervention</th>
<th>MDA with DHA-P</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivermectin dose</td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Highly seasonal (Fatick, Senegal)</td>
<td>3 rounds 1 month apart 1x400µg/kg: 74% 3x300µg/kg: 91% 1x400µg/kg: 67% 3x300µg/kg: 75%</td>
<td>3 rounds 1 month apart 1x400µg/kg: 50% 3x300µg/kg: 66% 1x400µg/kg: 31% 3x300µg/kg: 36%</td>
</tr>
<tr>
<td>Perennial (Equateur, DRC)</td>
<td>3 rounds 1 month apart 1x400µg/kg: 57% 3x300µg/kg: 79% 1x400µg/kg: 81% 3x300µg/kg: 81%</td>
<td>3 rounds 1 month apart 1x400µg/kg: 57% 3x300µg/kg: 79% 1x400µg/kg: 81% 3x300µg/kg: 81%</td>
</tr>
<tr>
<td>Perennial (Equateur, DRC)</td>
<td>3 rounds 4 months apart 1x400µg/kg: 57% 3x300µg/kg: 79% 1x400µg/kg: 81% 3x300µg/kg: 81%</td>
<td>3 rounds 4 months apart 1x400µg/kg: 57% 3x300µg/kg: 79% 1x400µg/kg: 81% 3x300µg/kg: 81%</td>
</tr>
</tbody>
</table>

### Table 1. Predicted reductions in malaria clinical incidence and prevalence for all intervention scenarios described in box 1.

Ivermectin only: Percentage reductions in clinical incidence (all ages) and annual mean slide prevalence (all ages) from simulations shown in Figure 2 (BF = Burkina Faso). SMC and ivermectin MDA: Absolute and incremental (in addition to SMC) percentage reduction in clinical incidence (in children <5 years old), in simulations shown in Figure 3. MDA with DHA-P and ivermectin: Absolute and incremental (in addition to MDA with DHA-P) percentage reduction in clinical incidence and slide prevalence in simulations shown in Figure 4. Equations for all ‘percentage reduction’ equations are in the Appendix, page 10.
Figure legends

Figure 1: (a) Modelled drug concentrations of 3x300µg/kg and 1x400µg/kg doses of ivermectin estimated using a PK-PD model fitted to data in Smit et al. (b) Data (dark pink points, with 95% confidence intervals) and modelled relationship between drug concentrations and Anopheles gambiae mosquito mortality (dark pink line) obtained using local polynomial regression, and the dose-response relationship (light pink line) used in a previous modelling study. (c) Hazard ratios for Anopheles gambiae mosquito mortality of 3x300µg/kg and 1x400µg/kg doses of ivermectin using relationships from (a) and (b).

Figure 2: Clinical incidence per 1,000 all-age population (a,b,c) and annual mean slide prevalence (c,d,e) after three rounds of ivermectin one month apart in three different transmission settings. The vertical pink lines indicate the timing of the ivermectin MDA rounds. Coverage is assumed to be 70% of all individuals over the age of 5. The baseline scenario assumes standard interventions only (LLINs, access to diagnosis and treatment).

Figure 3: Clinical incidence per 1,000 children ≤5 years old after four rounds one month apart of SMC, SMC + 1x400µg/kg ivermectin or SMC + 3x300µg/kg ivermectin in a highly seasonal (a) and seasonal (b) transmission setting with a pre-intervention mean annual slide prevalence of 30%. We assume ivermectin coverage of 70% in individuals over the age of five and SMC coverage of 90% children aged 3-59 months. The baseline scenario assumes standard interventions only (LLINs, access to diagnosis and treatment).

Figure 4: Clinical incidence per 1,000 all-age population (a,b,c) and annual mean slide prevalence (d,e,f) after three rounds of MDA with DHA-P, MDA with DHA-P + 1x400µg/kg ivermectin or MDA with DHA-P + 3x300µg/kg ivermectin in a highly seasonal moderate (a,d), and perennial moderate (b,e and c,f) transmission setting. The rounds are conducted either one month apart (a,d and b,e) or four months apart (c,f). Coverage is assumed to be 70% of all individuals over the age of 5. The baseline scenario assumes standard interventions only (LLINs, access to diagnosis and treatment).

Figure 5: Clinical incidence per 1,000 all-age population (a) and annual mean slide prevalence (b) after three rounds of MDA with DHA-P, MDA with DHA-P + 1x400µg/kg ivermectin or MDA with DHA-P + 3x300µg/kg ivermectin in a highly seasonal low transmission setting. Coverage is assumed to be 70% of all individuals over the age of 5. The baseline scenario assumes standard interventions only (LLINs, access to diagnosis and treatment).
Highly Seasonal Transmission  
(Fatick, Senegal)

Seasonal Transmission  
(Bougouriba, Burkina Faso)

Perennial Transmission  
(Equateur, DRC)

Clinical incidence per 1,000 (all ages)

Slide prevalence (all ages) (%)

Time (months)

Baseline  
1x400μg/kg  
3x300μg/kg

Slater et al, Lancet ID (in press); Confidential
Highly Seasonal Transmission
(Fatick, Senegal)

Clinical incidence per 1,000 children < 5 years old

Seasonal Transmission
(Bougouriba, Burkina Faso)

Baseline   SMC   SMC + 1x400μg/kg   SMC + 3x300μg/kg

Slater et al, Lancet ID (in press); Confidential
Highly Seasonal Transmission (Fatick, Senegal)  

Perennial Transmission (Equateur, DRC)  

Perennial Transmission (Equateur, DRC)

Clinical Incidence per 1,000 (all population)

Slide prevalence (%) (all population)

Time (months)

Baseline  
MDA (DHA–P)  
MDA (DHA–P) + 1x400μg/kg  
MDA (DHA–P) + 3x300μg/kg

Slater et al, Lancet ID (in press); Confidential